Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
9
×
boston blog main
9
×
boston top stories
9
×
life sciences
national blog main
national top stories
clinical trials
san francisco blog main
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
amgen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
san diego blog main
san diego top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
eli lilly
fda
novartis
alnylam pharmaceuticals
cancer
deals
fremanezumab
teva pharmaceutical
alder biopharmaceuticals
alirocumab
bristol-myers squibb
What
drug
9
×
new
9
×
medicines
approval
bio
companies
fda
biotech
brings
cholesterol
class
company
drugs
earlier
ipo
lead
migraine
million
ready
roundup
wave
won
year
acquire
adds
advantages
agreed
alliance
amgen
analysis
areas
arguments
bar
big
billion
biogen’s
biopharmaceutical
biosciences
bio’s
black
Language
unset
Current search:
new
×
drug
×
" boston blog main "
×
biotech
×
" boston top stories "
×
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines